News

Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...

While dabrafenib–trametinib may offer incremental QALYs in patients with BRAF-mutant stage III melanoma, it is not considered a cost-effective regimen, according to study findings.

Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.

Small-volume, short-duration infusions of bendamustine may result in lower acquisition costs and lower administration labor costs compared to large-volume, long-duration infusions, in patients with CLL and indolent NHL.

Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.

Adding daratumumab to bortezomib, melphalan, and prednisone is considered more cost-effective than bortezomib, melphalan, and prednisone alone for newly diagnosed MM.

The significant increase in direct costs of melanoma treatment in the Medicare population is associated with the adoption of recent novel therapies, especially for those patients with advanced stages of disease.

Study findings suggest not all oncologists view cost conversations as a best practice, and offer guidance to improve attitudes around these conversations.

The utilization of telehealth in oncology does not lead to worse efficiency or outcomes for patients, when compared with in-person care.

Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.